Anti-inflammatory drugs such as tocilizumab and siltuximab can inhibit the action of interleukin-6 (IL-6) and the interleukin-6 receptor (IL-6R), thereby reducing the CAR-T-associated CRS without impairing CAR-T activities or causing T cell apoptosis.154–159. This evidence concerns the gene IL6 and congenital rubella syndrome.